We performed pooled-DNA sequencing in 172 AD cases in APP, PSEN1, PSEN2, GRN, and MAPT in order to identify known pathogenic mutations and potentially functional novel variants associated with disease risk. The gene discussed is MAPT; the disease is Alzheimer disease.